Early Assessment of Anthracycline-induced Cardiotoxicity (CARDIOTOX)

Phase

N/A

Condition

Congestive Heart Failure

Chest Pain

Lymphoma

Treatment

N/A

Clinical Study ID

NCT00195897

2005-001-CHB

Ages 18-70
All Genders

Study Summary

Anthracycline-based chemotherapy is a key point of the treatment of patients with Hodgkin's and non-Hodgkin's lymphomas. However, cumulative doses are limited by cardiotoxicity, resulting in a marked left ventricular function impairment that may lead to heart failure.

The standard clinical approach to monitoring for anthracycline cardiotoxicity is based on cardiac function monitoring using echocardiography or radionuclide angiography. The aim of this study is to evaluate the usefulness of biochemical markers of cardiac injury (troponin and NT-proBNP) and structural changes on cardiac MR in predicting anthracycline cardiotoxicity.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Histologically proven lymphoma (Hodgkin's or non-Hodgkin's)
Age > 18 y/o and < 70 y/o
WHO score < or = 2
Life expectancy > 6 mo
Left ventricular ejection fraction > 50%
Informed consent

Exclusion

Exclusion Criteria:

Previous chemotherapy using anthracyclines
History of radiation therapy
History of congestive heart failure
History of chronic renal insufficiency
Contra indication to MR examination
Atrial fibrillation and significant arrhythmia
Pregnancy

Study Design

January 01, 2006

December 31, 2009

Connect with a study center

Centre Henri Becquerel
Rouen, 76038
France
Site Not Available
University Hospital of Rouen
Rouen, 76031
France
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.